TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Nurix Therapeutics
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics will present updated clinical data on bexobrutideg, a novel BTK degrader, at the ASH Annual Meeting, showcasing results in chronic lymphocytic leukemia and Waldenström macroglobulinemia treatments.

Insights
NRIX   positive

Company is presenting promising clinical trial data for its investigational drug bexobrutideg across multiple cancer types, indicating potential therapeutic advancements